2 weeks Ago By Yeon Choul-woong
Coreline Soft, a global leader in AI-powered chest imaging solutions, will participate in the British Society of Thoracic Imaging (BSTI) Annual Scientific Meeting (ASM) 2025, scheduled for April 28–29 in Birmingham, UK. Coreline Soft will showcase its flagship solution, AVIEW LCS Plus, an advanced 3-in-1 AI diagnostic platform that enables simultaneous detection of lung cancer, coronary artery calcification (CAC), and COPD from a single chest CT scan. AVIEW LCS Plus has been adopted in several of Europe’s most prominent national and multinational lung screening initiatives, including: - Germany’s HANSE Study, the pilot for the national lung cancer screening program - Italy’s RISP project, a leading model for population-based early detection - The 4ITRL consortium, a collaborative lung cancer screening effort spanning five European countries These partnerships reinforce AVIEW LCS Plus’s role as a validated and scalable AI solution trusted by health authorities and clinical leaders across Europe.
At BSTI ASM 2025, Coreline Soft will: - Present insights from real-world deployments of AVIEW LCS Plus in European screening programs - Discuss AI's integration into clinical workflow and policy frameworks - Explore the potential for collaboration with NHS-led pilot initiatives in the UK “We’re not only bringing AI technology, but also proven experience in clinical implementation at a national level,” said a Coreline Soft Europe official. “BSTI is the ideal platform to share how integrated AI screening is already redefining chest imaging outcomes across Europe.” Looking Ahead: AI-Powered Screening, Policy-Ready Platforms Backed by CE MDR Class IIb certification, AVIEW LCS Plus is positioned as a robust AI platform for scalable, evidence-based lung screening.
Its ability to detect incidental findings and support multidisciplinary decision-making makes it particularly relevant for early diagnosis, health policy alignment, and population health strategies..
